Skip to content
10-K

Annual Report

Oncotelic Therapeutics, Inc. OTLC

0001493152-26-016838

← back to feed
Filed
Apr 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Apr 14, 2026 444.2M sh
Shares Diluted FY 2025 · Dec 31, 2025 422.23M sh
Shares Diluted FY 2025 · Dec 31, 2024 404.4M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$1.38M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$740.28K
Stockholders Equity FY 2025 · Dec 31, 2025 $262.76M
Stockholders Equity FY 2025 · Dec 31, 2024 $8.25M
Current Liabilities FY 2025 · Dec 31, 2025 $18.14M
Current Liabilities FY 2025 · Dec 31, 2024 $19.2M
Total Liabilities FY 2025 · Dec 31, 2025 $131.36M
Total Liabilities FY 2025 · Dec 31, 2024 $19.2M
Current Assets FY 2025 · Dec 31, 2025 $1.2M
Current Assets FY 2025 · Dec 31, 2024 $134.21K
Total Assets FY 2025 · Dec 31, 2025 $393.09M
Total Assets FY 2025 · Dec 31, 2024 $26.68M
Eps Diluted FY 2025 · Dec 31, 2025 $0.59
Eps Diluted FY 2025 · Dec 31, 2024 −$0.01
Eps Basic FY 2025 · Dec 31, 2025 $0.59
Eps Basic restated FY 2025 · Dec 31, 2024 $0.01
Sga Expense FY 2025 · Dec 31, 2025 $3.18M
Sga Expense FY 2025 · Dec 31, 2024 $376.01K
Rd Expense FY 2025 · Dec 31, 2025 $4.36K
Net Income FY 2025 · Dec 31, 2025 $249.28M
Net Income FY 2025 · Dec 31, 2024 −$4.52M
Operating Income FY 2025 · Dec 31, 2025 −$3.19M
Operating Income FY 2025 · Dec 31, 2024 −$3.58M
Stock Issued FY 2025 · Jul 31, 2025 2.25M sh
Stock Issued FY 2025 · Jul 31, 2025 2.25M sh